Status:
RECRUITING
Autoreactive B Cells in Membranous Nephropathy
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Conditions:
Membranous Nephropathy
Eligibility:
All Genders
18+ years
Brief Summary
Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 rece...
Eligibility Criteria
Inclusion
- Patients inclusion criteria
- Males and females.
- Adults (\> 18 years old).
- Patients with biopsy-proven idiopathic MN, who are candidate to receive (prospective cohort) or who already received (retrospective cohort) a B-cell depleting treatment as per center clinical practice.
- Mental state is such that they are able to understand and give valid consent to the study;
- Written informed consent according to the guidelines of the Declaration of Helsinki.
- Healthy volunteers inclusion criteria
- Male and female (\>18 years) not known to suffer of any significant illness;
- Not assuming any medication or drug on a regular basis;
- Negative urine analysis (urine dipstick, multistick);
- Written informed consent according to the guidelines of the Declaration of Helsinki
Exclusion
- Patients exclusion criteria
- Reasonable possibility of a secondary cause of MN (e.g.systemic lupus erythematosus, active hepatitis B, malignancy, drugs such as gold salts and penicillamine).
- Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.
- Healthy volunteers exclusion criteria
- \- Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.
Key Trial Info
Start Date :
September 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT04095156
Start Date
September 12 2019
End Date
March 1 2026
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro di Ricerche Cliniche per le Malattie Rare " Aldo e Cele Daccò"
Ranica, BG, Italy, 24020